Introduction {#sec1-1}
============

Myocardial infarction (MI) is one of the most widely spread manifestations of cardiovascular disease, which is associated with imbalance between coronary blood supply and myocardial demand ([@ref1]). MI is a major public health concern and the leading cause of morbidity and mortality in the Western world, even in China. So far, morbidity and mortality due to MI have reached epidemic proportions, accounting for 16.7 million deaths/year worldwide ([@ref2]). Furthermore, MI can also cause other obvious symptoms, such as myocardial fibrosis ([@ref3]) and cardiac hypertrophy ([@ref4]). The specific mechanism involving MI have proved to be associated with oxidative stress ([@ref5]), apoptosis ([@ref6]), and inflammation ([@ref7]). Previous studies have demonstrated that oxidative stress could participate in myocardial structural damage in cardiac hypertrophy ([@ref8]). In addition, increasing evidence has indicated that the level or activities of endogenous antioxidants get altered in the myocardium in response to oxidative stress condi-tions ([@ref9]). The activities of some antioxidant enzymes, such as catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPX) decreased ([@ref10]), which can lead to added lipid peroxidation. The increase of lipid peroxides could lead to the formation of malondialdehyde (MDA), increase free radical production and decrease in antioxidant status ([@ref5]). Under the condition of oxidative stress, excessive production of reactive oxygen species (ROS) allows the release of pro-apoptotic factors from the mitochondria into the cytosol and thereby activating signs of endoplasmic reticulum stress and apoptotic cell death ([@ref11]). Several lines of evidence suggest that inflammation is a key process involved in mediating myocardial tissue damage after an ischemic event ([@ref12]). Neutrophils infiltrate the infarcted area where they can promote myocardial cell damage through the release of proteolytic enzymes, a myriad of inflammatory cytokines and chemokines, and the production of ROS ([@ref9]). Cytokines and chemokines, as well as ROS, eventually cause the loss of organ function ([@ref13]).

Traditional Chinese Medicines (TCMs) and their preparations have been widely used to prevent and treat diseases for thousands of years in China and other countries ([@ref14]). So far, in order to combat MI and related disease, researchers have found that TCMs with antioxidant activity such as *Vitex negundo* ([@ref15]), *Aegle marmelos* ([@ref16]), *Salvia miltiorrhiza* ([@ref10]), *Anemarrhena asphodeloides Bunge* ([@ref17]) have cardio-protective effects. *Erigeron breviscapus (vant.)*, a traditional Chinese medicinal plant, has a long history of medicinal use in Chinese medicine ([@ref18]). In general, *E. breviscapus* is extensively used in clinics to treat ischemic cardio-cerebral vascular diseases ([@ref19]). Scutellarin *(Scu)* is a flavonoid glycoside that is the main effective constituent of *E. breviscapine* ([@ref20]). *Scu* could significantly improve hemodynamics, micro-circulation and blood flow, dilate blood vessels, reduce the blood platelet count, activate K^+^ channels and block Ca^2+^ channels, and increase cerebral blood flow, etc ([@ref21]). In clinics, oral and injectable pharmaceuticals of *Scu* have been used for the treatment of myocardial ischemia, focal cerebral ischemia, angina pectoris, coronary heart disease, acute cerebral infarction, and paralysis induced by cerebrovascular diseases ([@ref22]). Therefore, in China and some other Asian countries, due to the distinguished efficacy of *Scu* in the clinical therapy, *Scu* research has become a hot topic in recent years.

Many studies have been carried out on cardioprotective effect of *E. breviscapus*. These studies have shown that *E. breviscapine* can significantly reduce MI size, and increase the serum concentration of Ca^2+^, Mg^2+^, Zn^2+^, and SOD in dog models of myocardial ischemia-reperfusion ([@ref23]). In rabbit models, *breviscapine* inhibited cell apoptosis and inflammatory injury, which was modulated by decreasing the expression of cytochrome C, Bax, caspase-3, Tumor Necrosis Factor (TNF-α) and nuclear factor kappa B (NFκB), increasing the expression of the B-cell lymphoma-2 (Bcl-2) and Bcl-2/Bax ratio ([@ref24]). In addition, *E. breviscapus* has a significant protective function in acute myocardial infarction (AMI) patients with reperfusion injury, which can effectively decrease the serum levels of interleukin- 6 (IL-6), TNF-α and MDA, and increase the levels of SOD and nitric oxide (NO) in serum ([@ref25]). Parallel results are also found in rat models ([@ref26]). Similarly, *Scu* can also decrease the infarction size and inhibit apoptosis of myocardial cells in AMI dog model. Furthermore, dose-response relationship of *Scu* is better than that of *E. breviscapine* ([@ref27]). Researchers have shown that *Scu* has a wide range of therapeutic properties, such as anti-apoptotic ([@ref28]), anti-oxidant ([@ref29]), anti-inflammatory ([@ref30]), and other effects. Neuroprotection of *Scu* was investigated in neurotoxicity induced by β-amyloid peptide (Aβ) in the rat brain ([@ref28]). The results indicated that *Scu* can attenuate the neurotoxicity of Aβ, by decreasing the levels of IL-6, interleukin-1 (IL-1β), and TNF-α, decreasing the percentage of apoptotic neurons, and increasing the levels of SOD and monoamine oxidase (MAO). In addition, researchers ([@ref29]) have investigated the cardioprotective effect of *Scu* on ischemia-reperfusion (I/R) in rat cardiomyocytes H9C2. The results indicated that *Scu* significantly protected cardiomyocytes from I/R injury-induced oxidative stress and apoptosis. This study demonstrates the protective role of *Scu* in ischemic heart disease. Therefore, we can also study the protective effect of *Scu* on MI rat model through oxidative stress, apoptosis, and inflammation-related pathways.

Isoprenaline (ISO), a β-adrenoceptor agonist is a catecholamine drug widely used in the treatment of allergic emergencies, status asthmatic, bronchial asthma, ventricular bradycardia, cardiac arrest, and glaucoma ([@ref31]). However, ISO can also induce side effects and cause obvious adverse reactions, which has been reported to produce MI in large doses ([@ref14]). After auto-oxidation, ISO generates highly reactive free radicals, alters tissue defense systems including chemical scavengers or antioxidant molecules and the antioxidant enzymes catalase, superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, and excessive accumulation of lipids in the heart tissue ([@ref32]). Researchers have found ISO-induced myocardial disorders in the heart of experimental animals similar to those seen in human myocardial ischemia ([@ref33]). Therefore, ISO has been widely used as a well-standardized model to produce MI in rats, in order to study the beneficial effects of many drugs on the processing of MI.

In the present study, we aim to investigate the protective role of *Scu* against ISO-induced MI in rats, and its functionary mechanism was also elucidated based on the antioxidant, anti-apoptotic, and anti-inflammatory activity of *Scu*.

Materials and Methods {#sec1-2}
=====================

Reagents {#sec2-1}
--------

Scutellarin (purity 98%) was purchased from JingZhu Co Ltd, Nanjing, China. The assay kits for MDA (A003-1), CAT (A007-1), inducible nitric oxide synthase (iNOS) (A014-1), glutathione (GSH) (A006-2), SOD (A001-3), BCA (A045-4) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China), and pentobarbital sodium, isoprenaline were purchased from Sigma--Aldrich Co, St Louis, MO, USA. The ELISA kits for troponin I (CTn-I) (ml7091103), troponin T (CTn-T) (ml7090091), lactate dehydrogenase (LDH) (m8009110), aspartate aminotransferase (AST) (ml5078923) were purchased from Enzyme-linked Biotechnology Co. Ltd, (Shanghai). *Salvia miltiorrhiza* injection was purchased from Sichuan Shenghe Co Ltd.

Experimental animals {#sec2-2}
--------------------

Animal experiments were approved by the Animal Care and Use Committee of the College of Animal Science, Fujian Agriculture and Forestry University, and the experiment was performed according to regulations and guidelines established by this committee. Thirty-six healthy adult male Sprague Dawley rats (weighing 180--200 g) were purchased from Shanghai Sikelai experimental animal Co Ltd. During the period of feeding SD rats, animals were acclimated to 22 ± 1°C and humidity was 65±10% RH, maintained under the light-dark cycle of 12 hr, free access to clean water and commercial food.

Experimental design {#sec2-3}
-------------------

Before commencement of experiments, the rats were fed adaptively for 5--7 days and divided into six groups of six animals each and treated as follows:

\(1\) Group 1 (G1), the control group, the rats were subcutaneously injected with normal saline (10 ml/kg) on the first day and then tail-intravenously injected with saline (10 ml/kg) for 7 consecutive days.(2) Group 2 (G2), model group, according to the experiments carried out by Radhiga Thangaiyan *et. al*. ([@ref34]) and Zhang Weili *et. al*. ([@ref35]), with some modifications; the rats were subcutaneously injected with ISO (45 mg/kg) on the first day and then tail-intravenously injected with saline (10 ml/kg) for 7 consecutive days.(3) Group3 (G3), the positive control group, the rats were subcutaneously injected with ISO (45 mg/kg) on the first day and then tail-intravenously injected with *S. miltiorrhiza* injection (10 mg/kg) for 7 consecutive days.(4) Groups 4--6 (G4-6), according to the experiments carried out by researchers ([@ref19], [@ref36], [@ref37]), with some modifications, the rats were subcutaneously injected with ISO (45 mg/kg) on the first day, and then tail-intravenously injected with *Scu* (10, 20, 40 mg/kg, respectively) for 7 consecutive days. Here, *Scu* was dispersed in saline by sonication for 10 min to obtain a homogeneous suspension, similar to the experimental method of Liu Qingfei *et. al*. ([@ref38]).

The rats were anesthetized with pentobarbital sodium and sacrificed on the ninth morning. Blood was collected and heart tissue was removed immediately, cleaned with ice saline, and dried with filter paper. The heart tissue was immediately frozen in liquid nitrogen and stored at -80°C for the determination and analysis of the following indicators.

A flowchart of the experiments involved in this study is shown in [Figure 1](#F1){ref-type="fig"}.

![Flow chart demonstrating the experimental approach](IJBMS-21-267-g001){#F1}

Determination of heart function indexes {#sec2-4}
---------------------------------------

After blood collection, serum was separated by centrifugation at 4°C at the speed of 3000 rpm for 10 min ([@ref39], [@ref40]). The activity of AST, LDH, and concentrations of CTn-I and CTn-T of the obtained serum were determined with the Elisa kit according to the manufacturer's instructions.

Determination of oxidative stress indexes and antioxidant enzymes in heart tissue {#sec2-5}
---------------------------------------------------------------------------------

0.1 g heart tissue was taken from -80°C refrigerator, and after precooling physiological saline was added at the ratio of 1:9. A high throughput tissue grinder was used to prepare the homogenate. Then the homogenate was centrifuged at 4°C at the speed of 3000 rpm for 10 min. The 10% homogenate protein concentration of the supernatant was determined by Nanjing BCA protein concentration kit. The activities of SOD and CAT and contents of MDA, iNOS, and GSH in the heart homogenate supernatant were determined according to the commercially available diagnostic kit instructions.

Histopathological examination of heart (HE staining) {#sec2-6}
----------------------------------------------------

Heart tissue was soaked in 4% poly formaldehyde solution and fixed for 24 hr, processed and paraffin embedded as per the standard protocol. Sections of 5 μm thickness were cut, deparaffinized, dehydrated, and stained with hematoxylin and eosin (H&E) for the estimation of pathological changes of heart by an optical microscope and photographed using a microscope digital camera.

Quantitative RT-PCR {#sec2-7}
-------------------

Heart Bax, Bcl~2~, P53, Caspase3, Caspase9, cyto-chrome C, Neutrophil gelatinase-associated lipocalin (NGAL), NFκB, IL-1β and IL-6 genes expression were quantified using real-time PCR. Total RNA was isolated from tissue samples using TransZolup (Transgen, China) according to the manufacturer's protocol. The purity and integrity of the total RNA were determined by spectrophotometry and agarose gel electrophoresis. The cDNA was prepared using the TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (Transgen, China) according to the manufacturer's instructions. In brief, 0.5 μg of RNA with 1 μl of Anchored Oligo Primer, 10 μl of Reaction Mix, 1 μl of TransScript RT/RI Enzyme Mix, 1μl of gDNA Remover in a DEPC-treated tube were mixed. Nuclease-free water was added to a final volume of 20 μl. The reaction condition for reverse transcription was performed according to the manufacturer's protocol.

Real-time quantitative PCR was conducted on the CFX384 Touch (BIO-RAD Laboratories, Inc) using SYBR premix Taq TM Kit (Takara, China). The housekeeping gene β-actin was used as a constitutive control for normalization. The primers for the target gene and β-actin were described as follows:

β-actin (111bp), forward: 5'--GAAGATCAAGATCATTGCTCC

T--3',

reverse: 5'--TACTCCTGCTTGCTGATCCA--3',

Bax (117bp), forward:5'--GGAGACACCTGAGCT GACCT--3',

reverse: 5'--ATCCTCTGCAGCTCCATGTT--3',

Bcl~2~ (120bp), forward:5'--AGGATTGTGGCCTTCTTT GA--3',

reverse: 5'--CAGATGCCGGTTCAGGTACT--3', P53 (119bp),

forward:5'--GCTTCGAGATGTTCCGAGAG--3',

reverse: 5'--AGACTGGCCCTTCTTGGTCT--3',

Caspase3 (147bp), forward:5'-- GAGACAGACAGTGGAACT

GACGATG--3',

reverse: 5'--GGCGCAAAGTGACTGGATGA--3',

Caspase9 (113bp), forward:5'--AGCCAGATGCTGTCCCA TAC--3',

reverse: 5'--ACCTGGGAAGGTGGAGTAGG--3',

cytochrome C (140bp), forward:5'--CCTTTGTGGTGTT

GACCAGC--3',

reverse: 5'-- CCATGGAGGTTTGGTCCAGT--3',

NGAL (123bp), forward:5'--ACATTCGTTCCAAGCTCC

AG--3',

reverse: 5'-- TGGCAAACTGGTCGTAGTCA--3',

IL-1β (123bp), forward:5'--CAGCAGCATCTCGACAAG AG--3',

reverse: 5'--AAAGAAGGTGCTTGGGTCCT--3',

NFκB (119bp), forward:5'--GGGCTGACCTGAGTCTTCT G--3',

reverse: 5'--GATAAGGAGTGCTGCCTTGC--3',

IL-6 (126bp), forward:5'--AGTTGCCTTCTTGGGAC TGA--3',

reverse: 5'--CCTCCGACTTGTGAAGTGGT--3',

Amplification was performed in a final volume of 10 μl including 0.8 μl of cDNA template, 0.5 μl of forward primer, 0.5 μl of reverse primer, 5 μl of SYBR Green premix Taq TM, and 3.2 μl of nuclease-free water. The qPCR conditions were as follows: initial denaturation for 30 sec at 94°C, followed by 40 cycles annealing for 5 sec at 94°C, and 30 sec at 56°C with subsequent melting curve analysis, increasing the temperature from 65°C to 95°C. The relative quantification among sample mRNA expression levels was calculated relative to ß-actin gene mRNA levels using the 2^△△Ct^ method.

Statistical analysis {#sec2-8}
--------------------

SPSS 19.0 software (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. All values are expressed as mean ± SD. Statistical comparisons were made using Student's t-test and one-way analysis of variance (ANOVA), followed by Tukey's test. The level of significance was set at *P*\<0.01.

Results {#sec1-3}
=======

Protect effects of Scu on heart injury induced by ISO in rats {#sec2-9}
-------------------------------------------------------------

The results are shown in [Table 1](#T1){ref-type="table"}. When compared to G1, the values of CTn-I, CTn-T, LDH, and AST in the serum of G2 were significantly higher. Compared to the model group, *Scu* administration groups (G4-6) had effectively reduced heart damage induced by ISO. AST, LDH, CTn-T, and CTn-I values in the serum of G6 were significantly lower than those of G2. The results of G3 were similar to those of G4 and G5.

###### 

Effects of Scutellarin (*Scu*) on troponin T (CTn-T), troponin I (CTn-I), lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) in rat serum with isoprenaline (ISO)-induced cardiotoxicity (n=6)

  Groups                            CTn-I(pg/mL)^[a](#t1f1){ref-type="table-fn"}^   CTn-T(ng/mL)^[a](#t1f1){ref-type="table-fn"}^                                  LDH(IU/L)^[a](#t1f1){ref-type="table-fn"}^   AST(U/L)^[a](#t1f1){ref-type="table-fn"}^
  --------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------- ----------------------------------------------------------------------------
  G1(saline)                        194.16±39.63^[c](#t1f3){ref-type="table-fn"}^   267.39±17.68^[c](#t1f3){ref-type="table-fn"}^                                  5.52±0.62^[c](#t1f3){ref-type="table-fn"}^   43.23±2.85^[c](#t1f3){ref-type="table-fn"}^
  G2(isoprenaline)                  298.96±48.05^[b](#t1f2){ref-type="table-fn"}^   405.56±54.30^[b](#t1f2){ref-type="table-fn"}^                                  8.22±1.43^[b](#t1f2){ref-type="table-fn"}^   64.28±2.39^[b](#t1f2){ref-type="table-fn"}^
  G3(ISO+10mg/g*S. miltiorrhiza*)   171.55±50.78^[c](#t1f3){ref-type="table-fn"}^   317.56±27.11^[c](#t1f3){ref-type="table-fn"}^                                  6.39±1.47                                    53.41±7.47^[b](#t1f2){ref-type="table-fn"}[c](#t1f3){ref-type="table-fn"}^
  G4(ISO+10mg/kg*Scu*)              195.83±20.92^[c](#t1f3){ref-type="table-fn"}^   330.91±27.48^[b](#t1f2){ref-type="table-fn"}[c](#t1f3){ref-type="table-fn"}^   6.60±1.23                                    47.89±10.57^[c](#t1f3){ref-type="table-fn"}^
  G5(ISO+20mg/kg*Scu*)              175.48±64.88^[c](#t1f3){ref-type="table-fn"}^   324.37±36.75^[b](#t1f2){ref-type="table-fn"}[c](#t1f3){ref-type="table-fn"}^   6.14±1.30^[c](#t1f3){ref-type="table-fn"}^   46.40±1.43^[c](#t1f3){ref-type="table-fn"}^
  G6(ISO+40mg/kg *Scu*)             167.36±28.42^[c](#t1f3){ref-type="table-fn"}^   280.95±29.70^[c](#t1f3){ref-type="table-fn"}^                                  5.13±0.71^[c](#t1f3){ref-type="table-fn"}^   46.32±3.81^[c](#t1f3){ref-type="table-fn"}^

Values represent mean±[SD]{.ul} of six animals;

Significantly different from saline group (G1) *P*\<0.01;

Significantly different from ISO group (G2) *P*\<0.01

Effects of Scu on oxidative stress indexes and antioxidant enzymes in hearts of rats {#sec2-10}
------------------------------------------------------------------------------------

According to [Table 2](#T2){ref-type="table"}, the activity of SOD, CAT, and content of GSH in heart tissue of G2 were significantly lower than those of G1, and the content of MDA and iNOS significantly increased. After *Scu* administration, the oxidative heart damage in rats significantly decreased. In G4-6, the activity of SOD, CAT, and content of GSH in heart tissue were significantly higher than those of the model group, and the activity was positively correlated with the dose of *Scu*. After administration of *Scu*, the MDA and iNOS contents in hearts of each administration group were significantly lower than those of the model group. The index of G3 was similar to those of G4 and G5. The results showed that *Scu* could increase the activity of antioxidant enzymes and decrease the oxidative stress induced by ISO.

###### 

Effects of Scutellarin (*Scu*) on superoxide dismutase (SOD), malondialdehyde (MDA), glutathione (GSH), catalase (CAT), and inducible nitric oxide synthase (iNOS) in rat heart tissue with isoprenaline (ISO)-induced cardiotoxicity (n=6)

  Groups                           SOD(U/mgprot)^[a](#t2f1){ref-type="table-fn"}^   MDA(nmol/mgprot)^[a](#t2f1){ref-type="table-fn"}^   GSH (μmol/[g]{.ul}prot)^[a](#t2f1){ref-type="table-fn"}^   CAT(U/mgprot)^[a](#t2f1){ref-type="table-fn"}^   iNOS(U/mgprot)^[a](#t2f1){ref-type="table-fn"}^
  -------------------------------- ------------------------------------------------ --------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------
  G1(saline)                       202.63±26.84^[c](#t2f3){ref-type="table-fn"}^    1.51±0.35^[c](#t2f3){ref-type="table-fn"}^          14.082±1.51^[c](#t2f3){ref-type="table-fn"}^               5.92±0.61^[c](#t2f3){ref-type="table-fn"}^       0.077±0.043^[c](#t2f3){ref-type="table-fn"}^
  G2(isoprenaline)                 140.85±16.97^[b](#t2f2){ref-type="table-fn"}^    4.15±0.65^[b](#t2f2){ref-type="table-fn"}^          7.53±1.11^[b](#t2f2){ref-type="table-fn"}^                 2.80±1.03^[b](#t2f2){ref-type="table-fn"}^       0.27±0.048^[b](#t2f2){ref-type="table-fn"}^
  G3(ISO+10mg/g*S.miltiorrhiza*)   224.80±60.25^[c](#t2f3){ref-type="table-fn"}^    1.74±0.63^[c](#t2f3){ref-type="table-fn"}^          12.18±3.86                                                 5.06±1.22^[c](#t2f3){ref-type="table-fn"}^       0.12±0.030^[c](#t2f3){ref-type="table-fn"}^
  G4(ISO+10mg/kg*Scu*)             221.05±14.06^[c](#t2f3){ref-type="table-fn"}^    1.845±0.52^[c](#t2f3){ref-type="table-fn"}^         14.72±2.30^[c](#t2f3){ref-type="table-fn"}^                3.62±0.53^[b](#t2f2){ref-type="table-fn"}^       0.14±0.036^[b](#t2f2){ref-type="table-fn"}[c](#t2f3){ref-type="table-fn"}^
  G5(ISO+20mg/kg*Scu*)             227.38±20.95^[c](#t2f3){ref-type="table-fn"}^    1.72±0.23^[c](#t2f3){ref-type="table-fn"}^          17.80±5.41^[c](#t2f3){ref-type="table-fn"}^                4.67±0.63^[c](#t2f3){ref-type="table-fn"}^       0.12±0.019^[c](#t2f3){ref-type="table-fn"}^
  G6(ISO+40mg/kg *Scu*)            251.77±21.82^[c](#t2f3){ref-type="table-fn"}^    1.63±0.40^[c](#t2f3){ref-type="table-fn"}^          18.41±3.30^[c](#t2f3){ref-type="table-fn"}^                6.50±1.32^[c](#t2f3){ref-type="table-fn"}^       0.093±0.038^[c](#t2f3){ref-type="table-fn"}^

Values represent mean±SD of six animals;

Significantly different from saline group (G1) *P*\<0.01;

Significantly different from ISO group (G2) *P*\<0.01

Effects of Scu on the pathological changes of rat hearts {#sec2-11}
--------------------------------------------------------

According to the HE staining of the heart tissue ([Figure 2](#F2){ref-type="fig"}), the heart tissue showed the normal histology of the control group, being composed of muscle cells and cardiomyocytes, with one centrally placed nucleus. In the model group, cardiac muscle fiber was disorganized and marked by cellular injury, patchy necrosis, enlargement in the size of cardiomyocytes, and a large number of inflammatory cell infiltration. The damages of *Scu* administration groups were lower than those of the model group. The G6 had obvious reduction effects and the cells were arranged neatly.

![The effects of Scutellarin *(Scu)* on histological changes of heart in rats (100×, HE). Control group (G1), ISO-model group (G2), ISO+10 mg/kg *S.miltiorrhiza* group (G3), ISO+10 mg/kg *Scu* group. (G4), ISO+20 mg/kg *Scu* group (G5), ISO+40 mg/kg *Scu* group (G6). The arrows in figs indicate inflammatory cell infiltration and hemorrhage](IJBMS-21-267-g002){#F2}

Scu attenuated apoptosis in heart of rats {#sec2-12}
-----------------------------------------

The effects of *Scu* on the mRNA expression of the apoptosis-associated gene in the heart induced by ISO are illustrated in [Figure 3](#F3){ref-type="fig"}. The expression of Bax, P53, Caspase3, Caspase9, and cytochrome C in G2 was signifycantly higher than G1, and then gradually decreased in dose-dependently after administration of *Scu*. The results of G3 were similar to those of G4. The results showed that *Scu* could decrease expression of the apoptosis-associated gene in the heart induced by ISO.

![The effects of Scutellarin (*Scu*) on the mRNA expression of the apoptosis-associated gene in rat hearts. Control group (G1), ISO-model group (G2), ISO+10 mg/kg *S. miltiorrhiza* group (G3), ISO+10 mg/kg *Scu* group (G4), ISO+120 mg/kg *Scu* group (G5), ISO+40 mg/kg *Scu* group (G6). Each point is the mean±SD (n= 4). a or b: Significantly different from the control (G1) or ISO (G2) group, respectively, *P*\<0.01 using ANOVA followed by Tukey's test](IJBMS-21-267-g003){#F3}

Scu attenuated inflammation in rat hearts {#sec2-13}
-----------------------------------------

The effects of *Scu* on the mRNA expression of inflammatory cytokines in heart induced by ISO are illustrated in [Figure 4](#F4){ref-type="fig"}. The expression of Neutrophil gelatinase-associated lipocalin (NGAL), NFκB, IL-1β, and IL-6 in G2 was significantly higher than G1, and then gradually decreased dose-dependently after administration of *Scu*. The results of G3 were similar to those of G4. The results showed that *Scu* could decrease expression of inflammatory cytokines in the heart induced by ISO.

![The effects of Scutellarin (*Scu*) on the mRNA expression of inflammation cytokine in rat hearts. Control group (G1), ISO-model group (G2), ISO+10 mg/kg *S. miltiorrhiza* group (G3), ISO+10 mg/kg *Scu* group (G4), ISO+120 mg/kg *Scu* group (G5), ISO+40 mg/kg *Scu* group (G6). Each point is the mean±SD (n=4). a or b: Significantly different from the control (G1) or ISO (G2) group, respectively, *P*\<0.01 using ANOVA followed by Tukey's test](IJBMS-21-267-g004){#F4}

Discussion {#sec1-4}
==========

ISO can cause a certain degree of damage to the heart clinical indicators, which are related to cardiac myocytes damages. After MI, the levels of troponin in the blood were increased. Troponin complex consists of three subunits of troponin C (TnC), TnT and TnI, cardiac TnC is not specific for the heart and is not employed for the MI diagnosis ([@ref41]). CTn-I and CTn-T are the most common indicators for the diagnosis of heart damage, and their elevation is an important indicator of heart damage in a laboratory test for detected MI ([@ref42]). The LDH enzyme activity can reflect the tissue damage degree, which mainly presents in myocardium, skeletal muscle, liver, and kidneys ([@ref43]). The concentrations that increase in the blood are indicative of cellular injury and inflammatory changes in tissues, particularly the heart ([@ref44]). Hence, LDH was usually used to diagnose MI. Myocardium contains high concentrations of AST, which are released into the blood when heart tissue is damaged. Thus, AST may be used to evaluate MI. Our research showed that compared with G1, the CTn-I, CTn-T, LDH, and AST in the model group were significantly increased, indicating that ISO induced a certain degree of damage to the hearts of rats. Compared with the model group, these indicators of G4-G6 were significantly reduced, indicating that *Scu* could effectively reduce cardiotoxicity induced by ISO.

In addition, from the perspective of histopatho-logy, the pathological changes of heart were found in the model group: cardiac muscle fibers were disorganized. Marked cellular injury, patchy necrosis, enlargement in the size of cardiomyocytes and accompaniment with a large number of inflammatory cell infiltration were observed in heart pathological sections. After administration of *Scu*, these lesions reduced by various degrees. It can be concluded that the administration of *Scu* to rats can effectively reduce the cardiotoxicity caused by ISO.

In the present study, the protective role of *Scu* in ISO-induced MI was studied by decreasing the levels of cardiac biomarkers related to MI and improving the pathological changes of heart. Previous researchers have demonstrated that MI has proven to be associated with oxidative stress ([@ref5]), apoptosis ([@ref6]), and inflammation ([@ref7]). Therefore, the protective effect of *Scu* on MI can be attributed to the following mechanisms.

Research indicates that oxidative stress is one of the mechanisms of ISO-induced cardiotoxicity, and the oxidative stress mediated by ROS plays an important role in ISO cardiotoxicity ([@ref32]). Once ISO enters the cell, it will generate highly cytotoxic free radicals and produce excessive ROS, resulting in loss of function and integrity of myocardial membranes ([@ref33]). ISO could interact with the antioxidant system and affect the antioxidant system and antioxidant enzymes, leading to oxidative damage of heart tissues. There is an obvious positive correlation between the degree of oxidative stress and the severity of tissue damage ([@ref14]).

In general, the free radicals produced are removed by the intracellular antioxidant enzymes such as SOD and CAT, thereby ensuring balanced generation and removal of free radicals ([@ref45]). When the free radicals accumulate excessively *in vivo* and cannot be removed by the antioxidant enzymes in time, the balance between the free radicals and the body defense systems will be destroyed, so as to promote the process of lipid peroxidation and cause cell damage ([@ref46]). The main product of lipid peroxidation process is MDA, so the MDA content of tissues can reflect the degree of lipid peroxidation and indirectly show the balance of free radical and antioxidant defense system ([@ref47]). INOS is inducible nitric oxide synthase, involved in the synthesis of NO *in vivo*, when in the state of oxidative stress, the expression of iNOS increased, resulting in excessive NO production, while excessive NO easily led to lipid peroxidation. GSH, SOD, and CAT are the important defense lines to resist free radicals ([@ref48]). They play an important role in the clearance of free radicals, the maintenance of free radical balance *in vivo*, the prevention of oxidative stress, and the accumulation of lipid peroxides ([@ref49]). The tissue content of these enzymes can be used as an indicator of antioxidant capacity. The results showed that ISO can reduce the GSH content in hearts of rats, inhibit the activity of SOD and CAT, which can lead to the accumulation of lipid peroxidation products and body damage. In our study, *Scu* can reduce the toxicity of heart induced by ISO in rats effectively by improving the antioxidant capacity and free radical scavenging ability, reducing the degree of oxidative stress and lipid peroxidation.

Multiple lines of evidence demonstrate that cell death is important in the pathogenesis of MI. Researchers have investigated the apoptotic pathway in ISO-induced MI ([@ref34], [@ref50]). The results show that administration of ISO in rats resulted in upregulation of the expressions of myocardial pro-apoptotic signaling proteins, including Bax, caspase-3, caspase-9, cytochrome C, and P53, and down-regulation of the expression of anti-apoptotic Bcl-2. In the process of apoptosis, oxidative stress can influence mitochondria and lysosomes. Researchers speculate that mitochondria and lysosome destabilization resulting in apoptosis may involve processes including the activation of procaspases or other proapoptotic proteins, that is to say, Bcl-2 family proteins and caspases are checkpoints of the apoptosis pathways ([@ref51]). Bax is an apoptosis promoter of Bcl-2 family, under the influence of apoptotic stimuli, such as oxidative stress, Bax could cause the release of cytochrome C and stimulate programmed cell death ([@ref52]). Bcl-2 is an anti-apoptotic member of the Bcl-2 family, by scavenging oxygen-free radicals inside the cells and repressing the release of cytochrome C into the cytoplasm, which play important roles in the regulation of the apoptotic pathway ([@ref53]). Caspase enzymes, including caspase-3 and caspase-9, play an essential role in the process of apoptosis ([@ref35]). Cytochrome C released into the cytoplasm, by proteolytic cleavage activation of procaspase-9 and then after activating caspase-9, procaspase-3 and caspase-3 were activated ([@ref54]). Active caspase-3 eventually causes the final-stage apoptosis ([@ref55]). p53 is a pro-apoptotic protein, and the data of the current study designate an association between the expression of Bax, caspase-3, and p53 and a decrease in the expression of Bcl-2 ([@ref56]). Researchers ([@ref57]) also evaluated the correlation between apoptosis and MI. The results suggested that after the treatment with crocetin, the level of caspase-3 and Bax significantly decreased and Bcl-2 increased in the myocardial tissues of MI rats compared with the MI group. Our results indicated that *Scu* can reduce the apoptosis induced by ISO in rat hearts effectively by decreasing the expression of Bax, caspase-3, caspase-9, p53, and increasing the expression of Bcl-2. NGAL is also referred to as lipocalin-2 (Lcn-2), a member of the lipocalin family of proteins. Under normal conditions, the concentration of NGAL is very low in kidneys, heart, stomach, lungs, etc ([@ref58]). However, the levels of NGAL maybe up-regulated in response to inflammation, intoxication, ischemia, and acute kidney injury ([@ref59]). Recent reports demonstrated that NGAL is not only a biomarker for renal injury but also a potentially valuable early marker of MI ([@ref60]). Recent studies have suggested that serum levels of NGAL in patients with chronic heart failure or AMI were significantly higher when compared with control subjects ([@ref61]). Furthermore, growing evidence suggests that high plasma NGAL levels may also be associated with inflammation. Upregulation of NGAL can be a pro-inflammatory induction of cytokines IL-6 ([@ref62]), interleukin-8 (IL-8) ([@ref63]), IL-1β ([@ref64]), and TNF-α ([@ref62]). Consistent with previous research results, our experimental results show that *Scu* reduced the mRNA expression of NGAL.

In addition, increasing evidence indicates that ISO induces a myriad of inflammatory cytokines ([@ref22]) and chemokines ([@ref12]) including translocation of the redox-sensitive transcription factor NFκB from the cytosol to the nucleus. The transcription factor NFκB plays an important role in regulating the production of inflammatory cytokines and promoting transcription of target genes, IL-1β, and IL-6, resulting in inflammatory responses caused by activation of proinflammatory cytokines ([@ref65]). IL-1β is the earliest cytokine-producing inflammatory reaction. It can stimulate the production of inflammatory mediators, chemotaxis of neutrophils, and other inflammatory cells into the lesion, which lead to a series of inflammations and tissue injury ([@ref66]). The mRNA expression of IL-1β is positively related to the degree of inflammation and can be used as an indicator of the severity and efficacy of the disease ([@ref67]). IL-1β inhibition is noteworthy for anti-inflammatory properties leading to inhibition of a cascade that activates NFκB, iNOS, and pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α ([@ref68]). IL-6 is involved in several inflammatory processes such as neutrophils recruitment and maturation ([@ref13]). Besides the direct activation and toxicity of vascular endothelial cells and inflammatory cells, IL-6 can catalyze and amplify inflammatory and toxic effects, resulting in tissue cell damage ([@ref69]). Researchers ([@ref36]) have investigated the hepatoprotective effect of *Scu* on diosbulbin B inducing liver injury in mice. The results indicated that *Scu* protects against the liver injury induced by diosbulbin B via inhibiting the NFκB signaling pathway, decreasing the increased serum levels of IL-6 and inhibiting the translocation of NFκB from the cytoplasm to the nucleus. Similarly, a study ([@ref30]) also reported the anti-inflammatory activity of *Scu* in microglial cells via suppressing lipopolysaccharide (LPS)-induced mRNA expressions of IL-1β in BV-2 cells and primary microglia, inhibiting LPS-induced NFκB nuclear translocation. Consistent with previous research results, our experimental results showed that *Scu* reduced the mRNA expression of inflammation cytokines NFκB, IL-1β, and IL-6, in the heart.

Conclusion {#sec1-5}
==========

In summary, the present study showed that *Scu* could reduce the damage of MI caused by ISO in rats, by improving the antioxidant, anti-apoptotic and anti-inflammatory capacity of the body. Therefore, *Scu* could serve as an important component in curing ischemic heart disease.
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